Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccination immunotherapy--an update.

C Doehn1, D Jocham

  • 1Department of Urology, University of Lübeck Medical School, Lübeck, Germany. doehn@medinf.mu-luebeck.de

Scandinavian Journal of Surgery : SJS : Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society
|August 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
Same author

[Update of the German S3 guideline on renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

Der Urologe. Ausg. A·2021
Same author

[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]

Der Urologe. Ausg. A·2020
Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020
Same journal

Long-term study to assess quality of life and cost outcomes of different delayed breast reconstruction techniques: A randomized controlled trial (GoBreast).

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026
Same journal

Cost efficiency of topical tranexamic acid in reduction mammaplasty surgeries.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026
Same journal

Implementation of robot-assisted transabdominal preperitoneal inguinal hernia repair: A prospective cohort study.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026
Same journal

Regional variations in surgeries for carpal tunnel syndrome and ulnar nerve disorders: A registry-based study in Finland.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026
Same journal

Two decades of abdominal aortic aneurysm repair in the Nordic countries from 1998 to 2017: A population-based registry analysis.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026
Same journal

Understanding personality in surgical career development: A cross-sectional study of Swedish medical students and surgeons.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026
See all related articles

Autologous tumor cell vaccines show promise for renal cell carcinoma, reducing progression risk after surgery with few side effects. Further research is needed for metastatic disease.

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Renal cell carcinoma (RCC) is considered an immunogenic tumor.
  • Organ-confined RCC is typically treated with surgical resection.
  • Adjuvant therapies may enhance outcomes post-surgery for RCC.

Purpose of the Study:

  • To review recent vaccination approaches for renal cell carcinoma (RCC).
  • To assess the efficacy and safety of autologous tumor cell vaccines in RCC treatment.
  • To explore the potential of vaccination for both early-stage and metastatic RCC.

Main Methods:

  • Review of published studies on RCC vaccination strategies over the past four years.
  • Analysis of clinical trial data, focusing on autologous renal tumor cell vaccines.

Related Experiment Videos

  • Examination of vaccine preparation, stimulation, administration, and patient outcomes.

    • Main Results:

    • A phase-III trial demonstrated reduced progression risk with an autologous renal tumor cell vaccine post-nephrectomy for RCC >2.5 cm, with minimal side effects.
    • Historical vaccination attempts for metastatic RCC showed limited clinical responses.
    • Current research focuses on developing more potent vaccines for metastatic RCC, with no phase-III trials ongoing.

    Conclusions:

    • Autologous tumor cell vaccination is a viable adjuvant strategy for non-metastatic renal cell carcinoma, offering reduced progression risk and good tolerability.
    • Existing vaccination approaches for metastatic renal cell carcinoma have shown limited efficacy.
    • Future efforts should concentrate on enhancing vaccine potency to improve outcomes for patients with advanced RCC.